<DOC>
	<DOCNO>NCT00798707</DOCNO>
	<brief_summary>The primary purpose study compare antidepressant efficacy safety two dos DVS SR ( 25 50 mg/day ) treatment adult Major Depressive Disorder . The study also assess change sexual function general functional quality life outcome .</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release ( DVS SR ) Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Adult , outpatient primary diagnosis Major Depressive Disorder ( depressive symptom least 30 day prior screen ) Hamilton Psychiatric Rating Scale Depression ( HAMD 17 ) total score &gt; = 20 Clinical Global Impressions ScaleSeverity ( CGIS ) score &gt; = 4 Clinical instability 25 % great increase/decrease HAMD 17 total score screen baseline Significant risk suicide assess clinician judgement , HAMD 17 Columbia SuicideSeverity Rating Scale score Other eligibility criterion also apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Major Depressive Disorder</keyword>
</DOC>